How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,699 results for

Intrauterine Device

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. A large bladder stone caused by the intravesical migration of an intrauterine contraceptive device: a case report (PubMed)

A large bladder stone caused by the intravesical migration of an intrauterine contraceptive device: a case report A wide variety of complications due to the extrauterine migration of intrauterine contraceptive devices have been reported in the literature. Here we describe the case of a large bladder stone formed around a migrated Copper T380A device that was neglected and detected 15 years after insertion.A 48-year-old Sri Lankan woman underwent a workup for lower urinary tract symptoms (...) and recurrent urinary tract infections over the previous 6 months. The radiographs showed a large bladder stone with an imprint of an intrauterine contraceptive device in the center of it. The device had been inserted 15 years previously. Two years after the insertion, it was considered to be missing, but our patient did not comply with the recommended follow-up. She had been completely asymptomatic until she developed lower urinary tract symptoms. After confirming the location of the stone via

Full Text available with Trip Pro

2017 Journal of medical case reports

162. Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management (PubMed)

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management Globally, endometrial cancer is the sixth leading cause of female cancer-related deaths. Non-atypical endometrial hyperplasia (EH), has a lifetime progression rate to endometrial cancer ranging from less than 5%, if simple without atypia, to 40%, if complex with atypia. Site specific, long-acting intrauterine devices (IUDs) provide fertility sparing, progestin-based EH

Full Text available with Trip Pro

2017 Healthcare

163. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: A retrospective review. (PubMed)

Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: A retrospective review. As the popularity of long-acting reversible contraception increases, so does the need for accurate data on method continuation in diverse clinical settings. We determined 2-year continuation rates for the levonorgestrel 52-mg intrauterine device, the copper T380A intrauterine device, and the 68-mg etonogestrel contraceptive implant in an academic healthcare system (...) with mixed-payer reimbursement.The purpose of this study was to examine the proportion and characteristics of women who continue intrauterine device and implant use to 2 years and to relate continuation to device type when controlling for patient characteristics.This retrospective chart review assessed University of Utah Healthcare System patients who had an intrauterine device or contraceptive implant inserted between January 1, 2004, and December 31, 2012. We identified users and dates of insertions

Full Text available with Trip Pro

2017 American Journal of Obstetrics and Gynecology

164. Intrauterine Morcellator Devices: The Icon of Hysteroscopic Future or Merely a Marketing Image? A Systematic Review Regarding Safety, Efficacy, Advantages, and Contraindications.

Intrauterine Morcellator Devices: The Icon of Hysteroscopic Future or Merely a Marketing Image? A Systematic Review Regarding Safety, Efficacy, Advantages, and Contraindications. The aim of this study was to analyze all available evidence regarding the use of intrauterine morcellator (IUM), for treatment of the most prevalent intrauterine benign lesions, compared to both traditional resectoscopy and conventional outpatient operative hysteroscopy in terms of safety, efficacy, contraindications (...) and MyoSure (Hologic, Marlborough, Massachusetts) was 12.3%. The available evidence allows us to consider IUM devices as a safe, effective, and cost-effective tool for the removal of intrauterine lesions such as polyps, myomas (type 0 and type 1), and placental remnants. Evidence regarding Truclear 5.0 suggests that it may represent the best choice for office hysteroscopy. Further studies are needed to confirm the available evidence and to validate the long-term safety of IUM in procedures for which

2017 Reproductive sciences (Thousand Oaks, Calif.)

165. Immediate postpartum levonorgestrel intrauterine device insertion and breast-feeding outcomes: a noninferiority randomized controlled trial. (PubMed)

Immediate postpartum levonorgestrel intrauterine device insertion and breast-feeding outcomes: a noninferiority randomized controlled trial. Immediate postpartum levonorgestrel intrauterine device insertion is increasing in frequency in the United States, but few studies have investigated the effect of early placement on breast-feeding outcomes.This study examined the effect of immediate vs delayed postpartum levonorgestrel intrauterine device insertion on breast-feeding outcomes.We conducted (...) this noninferiority randomized controlled trial at the University of Utah and the University of New Mexico Health Sciences Centers from February 2014 through March 2016. Eligible women were pregnant and planned to breast-feed, spoke English or Spanish, were aged 18-40 years, and desired a levonorgestrel intrauterine device. Enrolled women were randomized 1:1 to immediate postpartum insertion or delayed insertion at 4-12 weeks' postpartum. Prespecified exclusion criteria included delivery <37.0 weeks' gestational

2017 American Journal of Obstetrics and Gynecology Controlled trial quality: predicted high

166. Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women. (PubMed)

Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women. To estimate the effect of a 1% lidocaine paracervical nerve block on pain during intrauterine device (IUD) insertion compared with a sham block in adolescents and young women.We conducted a multisite, single-blind, sham-controlled randomized trial in adolescents and young women having a 13.5-mg levonorgestrel IUD inserted. Enrollment occurred at three family planning clinics

2017 Obstetrics and Gynecology Controlled trial quality: predicted high

167. Comment on 'Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial'. (PubMed)

Comment on 'Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial'. 28756404 2018 07 05 2045-2098 43 4 2017 Oct The journal of family planning and reproductive health care J Fam Plann Reprod Health Care Comment on 'Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial'. 342 10.1136/jfprhc (...) @stanford.edu. eng Letter 2017 07 29 England J Fam Plann Reprod Health Care 101087687 1471-1893 hormonal contraception human immunodeficiency virus intrauterine systems long-acting progestogens long-acting reversible contraception Competing interests: None declared. 2017 8 2 6 0 2017 8 2 6 1 2017 7 31 6 0 ppublish 28756404 jfprhc-2017-101827 10.1136/jfprhc-2017-101827

2017 The Journal of Family Planning and Reproductive Health Care Controlled trial quality: uncertain

168. Authors' response to 'Comment on 'Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial' '. (PubMed)

Authors' response to 'Comment on 'Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial' '. 29018110 2018 07 05 2045-2098 43 4 2017 Oct The journal of family planning and reproductive health care J Fam Plann Reprod Health Care Authors' response to 'Comment on 'Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic (...) ; tess@lawrie.com. eng Letter England J Fam Plann Reprod Health Care 101087687 1471-1893 human immunodeficiency virus intrauterine devices long-acting progestogens Competing interests: None declared. 2017 07 10 2017 07 11 2017 10 12 6 0 2017 10 12 6 0 2017 10 12 6 1 ppublish 29018110 jfprhc-2017-101864 10.1136/jfprhc-2017-101864

Full Text available with Trip Pro

2017 The Journal of Family Planning and Reproductive Health Care Controlled trial quality: uncertain

169. Comments on manuscript: vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial. (PubMed)

Comments on manuscript: vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial. 28189667 2017 10 19 2018 12 02 1879-0518 95 4 2017 04 Contraception Contraception Comments on manuscript: vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial. 434-435 S0010-7824(17)30038-0 10.1016/j.contraception (...) . 2017 Apr;95(4):435 28188744 Administration, Intravaginal Cesarean Section Double-Blind Method Female Humans Intrauterine Devices Misoprostol Pregnancy 2017 01 20 2017 01 21 2017 2 13 6 0 2017 10 20 6 0 2017 2 13 6 0 ppublish 28189667 S0010-7824(17)30038-0 10.1016/j.contraception.2017.01.012

2017 Contraception Controlled trial quality: predicted high

170. Visibility of Strings After Postplacental Intracesarean Insertion of CuT380A and Cu375 Intrauterine Contraceptive Device: A Randomized Comparative Study (PubMed)

Visibility of Strings After Postplacental Intracesarean Insertion of CuT380A and Cu375 Intrauterine Contraceptive Device: A Randomized Comparative Study To compare the incidence of visible strings after postplacental intracesarean insertion of Cu375 and CuT380A intrauterine contraceptive devices (IUD).This was a prospective, randomized comparative study. A total of 100 women fulfilling the inclusion and exclusion criteria underwent postplacental intracesarean insertion of either Cu375 IUD

Full Text available with Trip Pro

2017 Journal of obstetrics and gynaecology of India Controlled trial quality: uncertain

171. Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. (PubMed)

Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. Evidence from observational studies suggests an increased risk of HIV acquisition among women using depot medroxyprogesterone acetate (DMPA) contraception.Within the context of a South African programme to increase women's access to the intrauterine contraceptive device (IUD), we conducted a pragmatic, open-label, parallel-arm

Full Text available with Trip Pro

2017 Journal of Family Planning and Reproductive Health Care Controlled trial quality: predicted high

172. Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women. (PubMed)

Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women. To estimate the effect of a 1% lidocaine paracervical nerve block on pain during intrauterine device (IUD) insertion compared with a sham block in adolescents and young women.We conducted a multisite, single-blind, sham-controlled randomized trial in adolescents and young women having a 13.5-mg levonorgestrel IUD inserted. Enrollment occurred at three family planning clinics

2017 Obstetrics and Gynecology Controlled trial quality: predicted high

173. Vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective Cesarean section: a randomized double-blind clinical trial. (PubMed)

Vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective Cesarean section: a randomized double-blind clinical trial. The current study aims to evaluate if vaginal misoprostol (400 mcg) administered prior to intrauterine device (IUD) insertion increases the ease and success of insertion among women who had delivered only by elective cesarean delivery (CD).The current study was a randomized, double-blind, placebo-controlled trial conducted in Assiut Women's

2017 Contraception Controlled trial quality: predicted high

174. New Product Review: Intrauterine Ball (IUB) SCu300B MIDI

, the Intrauterine Ball (IUB™) SCu300B MIDI is a copper intrauterine device (Cu-IUD) comprised of copper beads with a total exposed copper surface of 300mm² strung on a flexible Nitinol (nickel/titanium alloy), PET-coated frame. Once the IUB is released from the 3.2mm diameter insertion tube into the uterus it coils into a spherical shape measuring 15mm in diameter. Download the product review in full here. Your download should start automatically. If not . Thinking about taking a qualification? Registration (...) New Product Review: Intrauterine Ball (IUB) SCu300B MIDI New Product Review: Intrauterine Ball (IUB™) SCu300B MIDI - February 2019 - Faculty of Sexual and Reproductive Healthcare New Product Review: Intrauterine Ball (IUB™) SCu300B MIDI - February 2019 New Product Review: Intrauterine Ball (IUB™) SCu300B MIDI - February 2019 Share this article 270def2e962ad577f33833df3d701209 Published on: 11 February 2019 File size: 252kb PDF File type: New Product Reviews Manufactured by OCON Medical Ltd

2019 Faculty of Sexual & Reproductive Healthcare

175. Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices

Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices - ACOG Menu ▼ Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices Page Navigation ▼ Number 735, May 2018 (Replaces Committee Opinion Number 539, October 2012) Committee on Adolescent Health Care Long-Acting Reversible Contraception Work Group This Committee Opinion was developed (...) : Implants and Intrauterine Devices ABSTRACT: The phenomenon of adolescent childbearing is complex and far reaching, affecting not only the adolescents but also their children and their community. The prevalence and public health effect of adolescent pregnancy reflect complex structural social problems and an unmet need for acceptable and effective contraceptive methods in this population. In 2006–2010, 82% of adolescents at risk of unintended pregnancy were currently using contraception, but only 59

2012 American College of Obstetricians and Gynecologists

176. Levonorgestrel-Releasing Intrauterine System 52 mg for Idiopathic Heavy Menstrual Bleeding

Technology Advisory Committee recommends publicly funding the 52-mg levonorgestrel-releasing intrauterine system for the treatment of idiopathic heavy menstrual bleeding Heavy menstrual bleeding can be painful, distressing and disruptive. Up to one-third of women between the ages of 15 and 55 experience heavy menstrual bleeding, and often the cause is unknown. However, treatment can reduce the symptoms and improve quality of life. Some options include medications, surgery, and a device called (...) the levonorgestrel-releasing intrauterine system. Health Quality Ontario Reviews the Levonorgestrel-Releasing Intrauterine System for Heavy Menstrual Bleeding The levonorgestrel-releasing intrauterine system is a minimally invasive and reversible device that is inserted in the uterus where it releases a hormone that suppresses and thins the lining of the uterus (endometrium), which can result in a reduction in the amount of bleeding. Currently, the insertion procedure is publicly funded in Ontario but the cost

2017 Health Quality Ontario

177. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. (PubMed)

Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. The objective was to measure the rate of unintended pregnancies in women using levonorgestrel-releasing intrauterine systems (LNG IUSs, releasing 20 mcg LNG daily) and copper intrauterine devices (IUDs) in a typical population of IUD users and to describe associated complications.A multinational, prospective, non-interventional

Full Text available with Trip Pro

2015 Contraception

178. Risk of Uterine Perforation with Levonorgestrel-Releasing and Copper Intrauterine Devices in the European Active Surveillance Study on Intrauterine Devices. (PubMed)

Risk of Uterine Perforation with Levonorgestrel-Releasing and Copper Intrauterine Devices in the European Active Surveillance Study on Intrauterine Devices. The objectives were to identify and compare the incidence of uterine perforation and other medically adverse events associated with levonorgestrel-releasing intrauterine systems (LNG-IUSs, releasing 20 mcg LNG daily) and copper intrauterine devices (IUDs) under routine conditions of use in a study population representative of typical (...) -three of the total 81 perforations were associated with previously suspected risk factors (e.g., breastfeeding, time since last delivery ≤36 weeks). No perforations led to serious illness or to injury of intra-abdominal or pelvic structures.Uterine perforation incidence in this study was low, with a benign clinical course thereafter. The LNG-IUSs and copper IUDs did not have clinically important differences in perforation rates.The European Active Surveillance Study on Intrauterine Devices

Full Text available with Trip Pro

2015 Contraception

179. Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction

Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction - GOV.UK GOV.UK uses cookies to make the site simpler. Search Sildenafil (Revatio and Viagra): reports of persistent pulmonary (...) hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction Sildenafil is not authorised for use in pregnancy for the treatment of intrauterine growth restriction. The STRIDER clinical trial, which was studying the use of sildenafil in pregnancy for intrauterine growth restriction, has been prematurely discontinued due to a higher incidence of persistent pulmonary hypertension of the newborn (PPHN) and neonatal mortality in the sildenafil arm

2018 MHRA Drug Safety Update

180. Effects of the levonorgestrel-releasing intrauterine device on the immune microenvironment of the human cervix and endometrium (PubMed)

Effects of the levonorgestrel-releasing intrauterine device on the immune microenvironment of the human cervix and endometrium There is little information regarding the impact of the intrauterine device on immune parameters of the upper female reproductive tract related to risk of HIV acquisition.We collected cervical and endometrial samples from women using the hormonal intrauterine device to study its effects on endocervical cytokines/chemokine concentrations, phenotypic markers of T cells (...) , responses of endometrial T cells to activation, and alterations of endometrial cellular infiltrates.Hormonal intrauterine device use was associated with: increased concentrations of inflammatory cytokines/chemokines (endocervix); increased coexpression of CXCR4 and CCR5 (endocervix and endometrium); increased coexpression of CD38 and HLADR (endocervix and endometrium); increased intracellular IL-10 production after T-cell stimulation (endometrium); and increased density of T cells, most notably

Full Text available with Trip Pro

2016 American journal of reproductive immunology (New York, N.Y. : 1989)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>